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Objective: The aim of this study was to examine the prevalence of major congenital malforma-
tions associated with antiepileptic drug (AED) treatment in pregnancy.
Patients and methods: Using data from The Health Improvement Network, we identified 
women who have given live birth and their offspring. Four subgroups were selected based on 
the AED treatment in early pregnancy, valproate, carbamazepine, lamotrigine and women not 
receiving AED treatment. We compared the prevalence of major congenital malformations within 
children of these four groups and estimated prevalence ratios (PRs) using Poisson regression 
adjusted for maternal age, sex of child, quintiles of Townsend deprivation score and indication 
for treatment.
Results: In total, 240,071 women were included in the study. A total of 229 women were 
prescribed valproate in pregnancy, 357 were prescribed lamotrigine and 334 were prescribed 
carbamazepine and 239,151 women were not prescribed AEDs. Fifteen out of 229 (6.6%) women 
prescribed valproate gave birth to a child with a major congenital malformation. The figures 
for lamotrigine, carbamazepine and women not prescribed AEDs were 2.7%, 3.3% and 2.2%, 
respectively. The prevalence of major congenital malformation was similar for women prescribed 
lamotrigine or carbamazepine compared to women with no AED treatment in pregnancy. For 
women prescribed valproate in polytherapy, the prevalence was fourfold higher. After adjust-
ments, the effect of estimates attenuated, but the prevalence remained two- to threefold higher 
in women prescribed valproate.
Conclusion: The results of our study suggest that lamotrigine and carbamazepine are safer 
treatment options than valproate in pregnancy and should be considered as alternative treatment 
options for women of childbearing potential and in pregnancy.
Keywords: pregnancy, valproate, lamotrigine, carbamazepine, adverse drug effects
Introduction
There have for some time been concerns as to whether certain antiepileptic medications, 
in particular valproate, may increase the risks of major congenital malformations.1–6 
Recently, the guidance on treatment with valproate was strengthened, and doctors in 
the European Union are now advised not to prescribe valproate for epilepsy or bipolar 
disorder to women of childbearing age and in pregnancy.7,8
While these concerns may have led many women to discontinue treatment either 
before or in early pregnancy,9 a number of women are still in need of antiepileptic 
drug (AED) treatment during pregnancy, regardless of whether this is for epilepsy or 
mental illnesses. Thus, women have to consider their own health as well as that of 
their future child. In some situations, alternative AED treatments may be available 
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for women of childbearing potential, but often evidence and 
guidance remain conflicting in terms of the safety of specific 
drugs.5,6,10–15
Our objective was to estimate and contrast the prevalence 
of major congenital malformations for the three most com-
monly used AED treatments, valproate, lamotrigine and 
carbamazepine9,16 during pregnancy in order to examine 
whether the latter two drugs provide a safer alternative to 
valproate treatment in pregnancy.
Patients and methods
We used data from The Health Improvement Network (THIN), 
a large primary care database that provides anonymized lon-
gitudinal general practice (family practice) data on patients’ 
clinical and prescribing records and includes data from ~6% of 
the UK population. Diagnoses and symptoms are recorded by 
practice staff using Read codes, a hierarchical coding system 
of >100,000 codes.17,18 The Read code system can be mapped 
to International Classification of Diseases, 10th revision, but 
in addition the Read codes include a number of symptom 
and administrative codes.18 Information on weight, height, 
smoking habits, history of alcohol and illicit drug problems 
as well as  antenatal care and birth details are also recorded. 
Prescriptions are issued electronically via the general practice 
computer systems. In addition, the database holds individual 
patient-level information about year of birth (birth months for 
individuals younger than 15 years of age), date of registration, 
dates of death and transfer out of the practice. There is also a 
household identifier, which is the same for individuals who 
live in the same household.
Over 98% of the UK population are registered with a 
general practitioner (GP, family doctor),19 and the database 
is broadly representative of the UK population.20,21 However, 
Blak et al20 demonstrated that THIN contained slightly 
more patients who lived in the most affluent areas. While 
antenatal care is often shared between general practice staff 
and midwives, the GP remains responsible for women’s 
general medical care during pregnancy, including prescrib-
ing medicines.
In this study, we utilized data from January 1, 1995, or 
when general practices met data quality standards21–23 and up 
to December 31, 2014, or when practices stopped contribut-
ing data to THIN.
Within THIN, we identified a group of pregnant women 
who gave live birth. These women were identified based on 
the recorded date of delivery; antenatal records, postnatal 
care records; the first day of last menstrual period (LMP) and 
the estimated delivery dates (EDD). A very small proportion 
(1%) of the pregnant women were identified from LMP and 
antenatal records alone. We subsequently linked the pregnant 
women’s clinical records to those of the children with the 
same household identifier if they were registered with the 
same general practice within 6 months after the children were 
born. Start of pregnancy was defined as the first day of LMP 
or 280 days before delivery if no records suggested a different 
duration of pregnancy. The sample was then restricted to one 
randomly chosen pregnancy per woman as pregnancies in the 
same woman may not be independent. We have used a similar 
approach in other studies on drug safety in pregnancy.9,16,24,25
Treatment groups
We identified four treatment groups based on the type of AED 
treatment prescribed 31–105 days after the start of the preg-
nancy (which covers the critical period for many major congeni-
tal malformations):26 valproate, carbamazepine, lamotrigine, as 
well as a group of women not prescribed AED, which contained 
women with no records of AED treatment in the pregnancy or 
28 days prior to LMP. Women who received polytherapy (i.e., 
more than one AED), which included valproate, were consid-
ered to belong to the valproate group and women who received 
polytherapy, which included carbamazepine and lamotrigine, 
were considered to belong to the carbamazepine group. This 
was done in order to make the groups mutually exclusive.
Outcome
All diagnostic codes for congenital malformations in the 
records of children linked to the pregnant women were iden-
tified using codes from the Read code chapter starting with 
P (congenital anomalies).18 Those diagnostic codes relating 
to major congenital malformations were then identified in 
consultation with a GP (IN) and in accordance with the 
EUROCAT guide.27
Covariates
We extracted information from the women’s electronic health 
records on age at delivery, calendar year of delivery, obesity, 
illicit drug use, alcohol problem and smoking status. As 
illicit drug use, alcohol problems and smoking status are 
often only recorded once, we considered records made up 
to 3 years before LMP or in pregnancy. For obesity, we con-
sidered individuals with a record of obesity or a body mass 
index of ≥30 kg/m2, which was recorded in the year before 
the LMP, but not in pregnancy. Information on the sex of 
the linked children was also extracted. We also considered 
treatments with other psychotropic medications including 
antipsychotics, antidepressants and anxiolytics, but in our 
initial investigations of the data we found no associations 
with these treatments and major congenital malformations. 
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This is supported by  previous research in THIN on these 
treatments.24,28,29 Therefore, we decided to exclude these 
treatments as potential confounders.
Data analysis
We tabulated the characteristics of the pregnant women 
treated with valproate, lamotrigine and carbamazepine and 
the pregnant women not treated with AEDs. We then cal-
culated the prevalence of major congenital malformations 
in each treatment group as the number of children with a 
record of major congenital malformations divided by the total 
number of children in each of the four groups.
Poisson regression was used to estimate relative 
prevalence ratios (PRs) comparing the prevalence of major 
congenital malformations in the children of women in vari-
ous treatment groups. Estimates of PRs were adjusted for 
 maternal age, sex of child, quintiles of Townsend deprivation 
score and indication for treatment (which were associated 
with the outcomes in the univariate analysis).
As a sensitivity analysis, we restricted the samples to 
those women with a record of epilepsy and repeated the 
abovementioned analyses.
All data analyses were performed in Stata 14.1.
Ethics
The scheme for THIN to obtain and provide anonymous 
patient data was approved by the National Health Service 
South-East Multicenter Research Ethics Committee (MREC) 
in 2002, and scientific approval for this study was obtained 
from Cedigem Strategic Data Medical Research’s Scientific 
Review Committee. As data was anonymized informed 
consent was not required.
Results
In total, 240,071 pregnancies were included in the study. 
There were 229 women prescribed valproate in early 
pregnancy, 334 prescribed carbamazepine, 357 prescribed 
lamotrigine and 239,151 not prescribed AEDs (Table 1). The 
Table 1 Characteristics of women in the four treatment cohorts
Characteristics Treatment status in first trimester
Valproate Carbamazepine Lamotrigine Not treated with AEDs
n % n % n % n %
Total 229 100 334 100 357 100 239,151 100
Age (years)
Mean (SD) 30 (5.6) – 31 (5.5) – 30 (5.3) – 31 (5.9) –
12–19 7 3.1 4 1.2 14 3.9 9,048 3.8
20–29 94 41 113 33.8 147 41.2 89,162 37.3
30–39 117 51.1 196 58.7 188 52.7 128,333 53.7
40–49 11 4.8 21 6.3 8 2.2 12,608 5.3
Year of delivery
1995–1999 34 14.8 47 14.1 7 2 18,626 7.8
2000–2004 65 28.4 98 29.3 50 14 59,706 25
2005–2009 78 34.1 106 31.7 154 43.1 86,303 36.1
2010–2014 52 22.7 83 24.9 146 40.9 74,516 31.2
Lifestyle variables
Obesity 25 10.9 35 10.5 38 10.6 14,697 6.1
Illicit drug use 9 3.9 11 3.3 5 1.4 1,560 0.7
Alcohol problems 3 1.3 5 1.5 4 1.1 1,252 0.5
Smoker 69 30.1 63 18.9 82 23 47,069 19.7
Townsend score
1 31 13.5 71 21.3 65 18.2 54,674 22.9
2 29 12.7 59 17.7 67 18.8 46,081 19.3
3 38 16.6 73 21.9 66 18.5 48,922 20.5
4 66 28.8 58 17.4 79 22.1 45,599 19.1
5 55 24 63 18.9 62 17.4 33,739 14.1
Missing 10 4.4 10 3 18 5 10,136 4.2
Indication
Unknown indication 8 3.5 17 5.1 7 2 219,849 91.9
Severe mental illness or depression 14 6.1 19 5.7 6 1.7 16,458 6.9
Epilepsy 207 90.4 298 89.2 344 96.4 2,844 1.2
Child characteristics
Male 111 48.5 186 55.7 180 50.4 122,091 51.1
Abbreviations: AEDs, antiepileptic drugs; SD, standard deviation.
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mean age of women prescribed valproate and lamotrigine 
was 30 years compared to 31 years in women not prescribed 
AEDs and women prescribed carbamazepine. For valproate 
and carbamazepine, 90% had a record of epilepsy and 6% had 
a record of severe mental illnesses (schizophrenia or bipolar 
disorder) or depression, while 96% of the women prescribed 
lamotrigine had a record of epilepsy and 2% had a record 
of severe mental illnesses or depression (Table 1). A larger 
proportion of women prescribed valproate, carbamazepine 
and lamotrigine had records of illicit drug use (1.4%–3.9%), 
alcohol problems (1.1%–1.5%) and obesity (10.5%–10.9%) 
than women not prescribed AED treatment (Table 1). More 
women among the valproate treatment group were smokers 
(30%) than the other groups (19%–23%). Fewer boys than 
girls (48.5%) were born to women who were treated with 
valproate, whereas more boys than girls were born to women 
prescribed carbamazepine (55.7%) or lamotrigine (50.4%) 
and women not prescribed AEDs (51.1%; Table 1). The com-
monest major congenital malformations were cardiovascular 
malformations including ventricular septal defect and atrial 
septal defect. Other common malformations include hypo-
spadias and cleft palate (Table S1).
Fifteen (6.6%) women prescribed valproate in pregnancy 
gave birth to a child with a major congenital malformation 
in comparison to eleven (3.3%) women prescribed carbam-
azepine and ten (2.8%) women prescribed lamotrigine and 
5,315 (2.2%) of women not prescribed AEDs. Finally, five 
(9.4%) women prescribed valproate in polytherapy gave birth 
to a child with a major congenital malformation.
There was no increased prevalence of major congenital 
malformation among children of women prescribed carbam-
azepine or lamotrigine in comparison to women not receiving 
AEDs (Table 2). In contrast, children of women prescribed 
valproate in pregnancy had a nearly threefold increased 
 prevalence of major congenital malformation in compari-
son to women not receiving AEDs. For women prescribed 
valproate in polytherapy, the prevalence was fourfold higher 
(Table 2). After adjustments for maternal age, indication for 
treatment, social deprivation and sex of child, the prevalence 
associated with valproate attenuated, but was still two to 
threefold higher in women prescribed valproate (all valpro-
ate vs not treated with AED: adjusted PR [PR
adj
] 2.19; 95% 
confidence interval (CI): 1.32–3.64; polytherapy valproate 
vs not treated with AED: PR
adj
 2.98; 95% CI: 1.29–6.88; 
Table 2). Although the prevalence of obesity, illicit drug use, 
alcohol problems and smoking varied among the four treat-
ment groups, there were no associations between these and 
the prevalence of major congenital malformations.
A direct comparison between children of women pre-
scribed valproate and women prescribed lamotrigine/carba-
mazepine revealed that the adjusted prevalence was twofold 
higher for valproate (PR
adj
 2.33; 95% CI: 1.21–4.50; Table 2).
Restricting the samples to individuals with a record of 
epilepsy provided similar estimates of prevalence and PRs 
to the primary analyses (Table 3).
Discussion
The results of our study suggest that the prevalence of major 
congenital malformations among children of women treated 
with carbamazepine or lamotrigine was comparable to the 
prevalence in women not treated with AEDs. However, we 
found a two- to threefold increased prevalence of major con-
genital malformations among children of women treated with 
valproate in pregnancy compared to children of women not 
prescribed AEDs. Similar increased prevalence was observed 
when comparisons were made between children of women 
treated with valproate and carbamazepine or lamotrigine. 
Finally, the prevalence of major congenital malformation 
Table 2 Prevalence and results from unadjusted and adjusted analyses of PRs and 95% CIs of MCM 
Comparisons made 
between
Total (N) MCM (n) Prevalence per  
100 live births (95% CI)
PRunadj 95% CI PRadj* 95% CI
No AED 239,151 5,315 2.22 (2.16–2.28) 1 – 1 –
Valproate 229 15 6.55 (3.71–10.57) 2.95 (1.81–4.81) 2.19 (1.32–3.64)
No AED 239,151 5,315 2.22 (2.16–2.28) 1 – 1 –
Valproate polytherapy 53 5 9.43 (3.13–20.66) 4.24 (1.86–9.69) 2.98 (1.29–6.88)
No AED 239,151 5,315 2.22 (2.16–2.28) 1 – 1 –
Valproate monotherapy 176 10 5.68 (2.76–10.20) 2.56 (1.40–4.67) 1.94 (1.05–3.61)
No AED 239,151 5,315 2.22 (2.16–2.28) 1 – 1 –
Carbamazepine 334 11 3.29 (1.66–5.82) 1.48 (0.80–2.74) 1.09 (0.57–2.09)
No AED 239,151 5,315 2.22 (2.16–2.28) 1 – 1 –
Lamotrigine 357 10 2.80 (1.35–5.09) 1.26 (0.69–2.31) 0.95 (0.51–1.79)
Lamotrigine/carbamazepine 691 21 3.04 (1.89–4.61) 1 – 1 –
Valproate 229 15 6.55 (3.71–10.57) 2.16 (1.15–4.04) 2.33 (1.21–4.50)
Note: *Adjusted analyses include adjustments for maternal age, sex of child, quintiles of Townsend deprivation score and indication for treatment.
Abbreviations: PR, prevalence ratio; CI, confidence interval; PRunadj, unadjusted PR; PRadj, adjusted PR; AEDs, antiepileptic drugs; MCM, major congenital malformations.
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was higher among children of women who were treated with 
valproate as polytherapy compared to monotherapy.
Our findings are in line with previous studies on valproate 
demonstrating an increased prevalence of congenital malfor-
mations associated with valproate treatment in pregnancy, in 
particular, for those who received valproate in polytherapy.3,4 
A recent systematic review suggests the prevalence of major 
congenital malformations among children of women receiv-
ing valproate in monotherapy was as high as 10.93% (95% 
CI: 8.91 to 13.13),6 somewhat higher than our estimates for 
valproate monotherapy (5.68%; 95% CI: 2.76 to 10.20). The 
same review highlights, however, that there may be a dose 
effect associated with valproate treatment.6
Our estimates of major congenital malformations among 
children of women receiving lamotrigine (2.80%; 95% CI: 
1.35 to 5.09) were similar to the pooled estimate from seven 
studies (2.31%; 95% CI: 1.87 to 2.78).6 Mølgaard-Nielsen 
and Hviid13 examined the overall risks associated with the 
use of newer AEDs in pregnancy using data from Danish 
population registries and found that major birth defects 
were diagnosed in 38 of 1,019 infants (3.7%) exposed to 
lamotrigine during the first trimester, but the prevalence 
was not elevated compared to women not treated with AEDs 
(adjusted prevalence odds ratios, 1.18; 95% CI: 0.83 to 1.68). 
Similar observations were made by Cunnington et al10 based 
on the data from the International Lamotrigine Pregnancy 
Registry. However, there has been some debate as to whether 
lamotrigine exposure in pregnancy is associated with orofa-
cial malformations, due to conflicting evidence.5,6,30,31
For carbamazepine, a large systematic review identified a 
prevalence of congenital malformations of 3.3% (95% CI: 2.7 
to 4.2),11 remarkably similar to our findings. Another systematic 
review found a slightly higher prevalence of 4.93% (95% CI: 
3.84 to 6.16), once they took into account variations between 
studies.6 Jentink et al11 suggested an elevated prevalence of spina 
bifida in children born to women treated with carbamazepine 
compared to women not treated with AEDs during pregnancy, 
but the prevalence associated with carbamazepine was only 
one-fifth relative to valproate treatment. Other studies have 
suggested associations between carbamazepine and orofacial 
malformations, but insufficient data are available to refute or 
confirm increased prevalence of these specific malformations 
in children of women treated with carbamazepine.6
While we could not identify a difference in the preva-
lence of major congenital malformations between children 
of women treated with carbamazepine and lamotrigine, 
Weston et al’s6 meta-analysis suggested that major congeni-
tal malformation is between 1% and 2% higher in children 
of women receiving carbamazepine compared to children of 
women receiving lamotrigine. However, the prevalence of 
major congenital malformations for both carbamazepine and 
lamotrigine was substantially lower than that for valproate.6
We found that the prevalence of major congenital malfor-
mations did not vary substantially for lifestyle characteristics 
such as smoking, alcohol problems, obesity and illicit drug 
use. However, it is possible that the impact of these charac-
teristics is more specific. For example, previous studies have 
documented significant associations between obesity and 
prevalence of congenital heart anomalies.24,32 Petersen et al24 
also  demonstrated associations between history of alcohol 
problems, illicit drug use and congenital heart anomalies.
Strength and limitations
The strength of this study is that it includes information from 
a large group of pregnant women and their offspring where 
information on drug treatment and pregnancy outcomes 
Table 3 Prevalence and results from unadjusted and adjusted analyses of PRs and 95% CI of MCM in children of women with a record 
of epilepsy
Comparisons made 
between
Total (N) MCM (n) Prevalence per 100 
live births (95% CI)
PRunadj 95% CI PRadj 95% CI
No AED 2,844 86 3.02 (2.42–3.73) 1 – 1 –
Valproate 207 15 7.25 (4.06–11.95) 2.40 (1.38–4.14) 2.33 (1.34–4.04)
No AED 2,844 86 3.02 (2.42–3.73) 1 – 1 –
Valproate polytherapy 50 5 10.00 (3.25–23.33) 3.31 (1.34–8.15) 2.81 (1.13–7.01)
No AED 2,844 86 3.02 (2.42–3.73) 1 – 1 –
Valproate monotherapy 157 10 6.37 (3.05–11.71) 2.11 (1.09–4.05) 2.14 (1.11–4.13)
No AED 2,844 86 3.02 (2.42–3.73) 1 – 1 –
Carbamazepine 298 10 3.36 (1.61–6.17) 1.11 (0.58–2.14) 1.09 (0.56–2.10)
No AED 2,844 86 3.02 (2.42–3.73) 1 – 1 –
Lamotrigine 344 9 2.61 (1.20–4.97) 0.87 (0.44–1.72) 0.88 (0.44–1.75)
Lamotrigine/carbamazepine 642 19 2.96 (1.78–4.62) 1 – 1 –
Valproate 207 15 7.25 (4.06–11.95) 2.59 (1.24–4.82) 2.65 (1.32–5.30)
Abbreviations: PR, prevalence ratio; CI, confidence interval; PRunadj, unadjusted PR; PRadj, adjusted PR; MCM, major congenital malformations; AEDs, antiepileptic drugs.
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were recorded prospectively and therefore were not subject 
to recall bias. We were able to evaluate the prevalence of 
valproate, carbamazepine and lamotrigine within the same 
study, and as the results of our findings for valproate are in 
line with previous research it may bring further validity to 
our findings regarding lamotrigine and carbamazepine.
One of the limitations of our study is that we were unable 
to examine the prevalence of specific congenital malforma-
tions such as spina bifida and orofacial malformation as 
such malformations are rare and therefore require very large 
sample sizes to evaluate prevalence with confidence.33
Our study included pregnancies which resulted in live 
births. Hence, it is possible that we may have underestimated 
the prevalence of major congenital malformations associated 
with AED treatment in pregnancy. This would happen if AED 
treatment in pregnancy leads to increased risk of miscarriage 
and still birth.
We could not perform a direct validation of the records 
of congenital malformations in THIN. However, a study on 
recording of congenital malformations in UK primary care 
was performed using data on 188 potentially major congenital 
malformations from the General Practice Research Database 
(which is similar in structure to THIN). This study was able 
to verify 160 malformations (85.1%) as the malformation 
indicated by the computerized records ranging from 91.7% of 
those cases verified using photocopied medical records and 
77.9% of cases verified using free text.34 Furthermore, our 
prevalence estimate (2.2%) in children born to women not 
treated with AEDs during pregnancy is similar to the estimates 
from British Isles Network of Congenital Anomaly Registers 
(BINOCAR).35 BINOCAR collated data from six regional 
registers covering ~36% of the births in England and Wales. 
Their latest estimate based on data collected in 2012 was 186 
per 10,000 births (equivalent to 1.86%).35
Clinical implications
The results of our study support treatment with lamotrigine 
and carbamazepine in pregnancy as a safer alternative to val-
proate. However, women and health-care professionals need 
to strike a balance between effectiveness and safety when 
considering treatment options bearing in mind that for some 
women switching to carbamazepine or lamotrigine may not 
be a suitable treatment option.7 Alternative treatment options 
may be considered in this situation, but limited evidence is 
available on many AEDs.6
Conclusion
The results of our study suggest that lamotrigine and car-
bamazepine are safer treatment options than valproate in 
pregnancy and both should be considered as treatment for 
women of childbearing potential and in pregnancy.
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Table S1 The 50 most commonly recorded Read codes for 
major congenital malformations
Read codes Description
P54..00 Ventricular septal defect
PC60.00 Hypospadias
PA5..00 Congenital hypertrophic pyloric stenosis
P550.00 Atrial septal defect NOS
P90..00 Cleft palate
PD23.11 Congenital dilated renal pelvis
PE1..12 Sternomastoid tumor
P71..00 Coarctation of aorta
PD34.11 Duplex kidneys
P52..00 Tetralogy of Fallot
PF0..00 Polydactyly – supernumerary digits
PG0y000 Brachycephaly
P92..00 Cleft palate with cleft lip
PD23.00 Congenital hydronephrosis
P55..00 Ostium secundum atrial septal defect
PG0z.11 Dysmorphic features
PB26.00 Imperforate anus
PF1..00 Syndactyly – webbing of digits
PG71.00 Gastroschisis
P6y2.00 Pulmonary infundibular stenosis
PB30.00 Hirschsprung’s disease
PC33.00 Bicornuate uterus
PF13.11 Webbed toes
P9…00 Cleft palate and lip
PF01.00 Accessory fingers
P21..00 Microcephalus
P91..00 Cleft lip (harelip)
PD11.00 Polycystic kidney disease
P360.00 Congenital ptosis
PG03.00 Craniosynostosis
P1…00 Spina bifida
PD02.00 Congenital absence of kidney
PG0C.00 Pierre–Robin syndrome
PD13.11 Multicystic kidney
P6z..00 Congenital heart anomaly NOS
PH3y200 Epidermolysis bullosa
P51..00 Transposition of great vessels
PKy9300 Prader–Willi syndrome
P641.00 Bicuspid aortic valve
P67..00 Hypoplastic left heart syndrome
P602.00 Congenital pulmonary stenosis
PK5..00 Tuberous sclerosis
P31..00 Microphthalmos
P63..00 Congenital aortic valve stenosis
PH1..00 Ichthyosis congenital
P344200 Coloboma of iris
P3y0.00 Ocular albinism
P80..00 Choanal atresia
PA30.00 Atresia of esophagus
PC60312 Hypospadias, glandular
Abbreviation: NOS, not otherwise specified.
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